<DOC>
	<DOCNO>NCT02397083</DOCNO>
	<brief_summary>The goal clinical research study learn Mirena intrauterine device ( levonorgestrel IUD ) , alone combination everolimus , effective treatment endometrial hyperplasia and/or early-stage endometrial cancer .</brief_summary>
	<brief_title>Phase II Study Intrauterine Device ( IUD ) Alone Combination With Everolimus Endometrial Cancer</brief_title>
	<detailed_description>Stage 1 Study Visits : The Levonorgestrel IUD : This study 2 stage . If find eligible take part study , Stage 1 , receive levonorgestrel IUD . The levonorgestrel IUD T-shaped birth control device make flexible plastic . It design prevent pregnancy release hormone call levonorgestrel , type progesterone . Progesterone common type hormone use prevent pregnancy . The IUD place exam pelvis . The uterine size measure IUD place directly uterus . This placement may do time dilation curettage ( D &amp; C , explain ) routine clinic visit . Removal IUD typically do clinic visit routine pelvic exam . The IUD string locate , grasp , use remove device . Study Surgery IUD Placement : On Day 1 ( within 1 week screen ) standard care procedure call dilation curettage ( D &amp; C ) confirm diagnosis . You would procedure even take part study . For procedure , pelvic exam , receive general anesthesia put sleep . You may also receive medication numb cervix . During procedure small amount tissue scrap uterus . You sign separate consent form describe procedure risk detail . During D &amp; C , levonorgestrel IUD place uterus . If recently D &amp; C , procedure need repeat . Instead , IUD place clinic visit . About 1 week surgery , study staff review surgery pathology result . If result show change diagnosis hyperplasia early-stage cancer , doctor decide still eligible take part study . If pathology result show grade 2 high cancer uterus , unable take part study . The levonorgestrel IUD remove operating room surgery removal disease outside uterus . You may also levonorgestrel IUD remove clinic . At 4 week surgery , physical exam , include pelvic exam . Placement levonorgestrel IUD check pelvic exam . In addition , may ultrasound uterus confirm location IUD . If IUD correct location , replace visit . Stage 1 Study Visits : At 3 month IUD placement , endometrial biopsy ( biopsy uterine lining ) check status disease . This standard care would do even take part study . If biopsy show disease gotten bad , take study treatment option discuss . If disease appear become stable , continue Stage 2 study ( describe ) . You also physical exam blood ( 2 tablespoon ) draw routine test visit . If disease appear respond completely , standard care biopsy 3 month later confirm response . If confirm , follow every 6 month standard care biopsy disease appear get bad and/or physician decide remove IUD come study . If complete response confirm 6-month biopsy visit , take study doctor talk option include surgical non-surgical treatment . Stage 2 Study Groups : If 3 month IUD placement disease remain stable , assigned study group . You randomly assign ( roll dice ) 1 2 arm . This do one know one arm better , , bad arm . - If Arm 1 , continue levonorgestrel IUD alone . - If Arm 2 , receive everolimus every day addition continue levonorgestrel IUD . Stage 2 Study Drug Administration : If Arm 2 , 3 month IUD placement , take everolimus 1 time day mouth time every day . You take either consistently food every day consistently without food every day . Each cycle Stage 2 28 day . Stage 2 Study Visits -- Arm 1 : If Arm 1 , 6 Months IUD placement . - You physical exam , include pelvic exam . - You endometrial biopsy check status disease . If disease appear get good stay . You follow every 3 month standard care biopsy disease appear get bad and/or physician decide remove IUD come study . You physical exam biopsy 9 month 1 year . If disease appear gotten bad 9-month 1-year biopsy , disease stayed time 1-year biopsy , come study doctor talk option include surgical non-surgical treatment . If complete response time 1-year biopsy , standard care biopsy 3 month later confirm response . If confirm , standard care biopsy every 6 month disease appear get bad and/or physician decide remove IUD . Stage 2 Study Visits -- Arm 2 : If Arm 2 , Day 1 Cycle : - You physical exam , include pelvic exam . - Blood ( 2 tablespoon ) draw routine test . - If doctor think need , blood ( 1 teaspoon ) drawn check hepatitis check liver function . If Arm 2 , Cycles 3 , 6 9 : - You physical exam , include pelvic exam . - Blood ( 2 tablespoon ) draw routine test . - You follow-up endometrial biopsy check status disease . - If doctor think need , blood ( 1 teaspoon ) drawn check liver function . If disease appear completely responded time Cycle 9 biopsy , endometrial biopsy confirm response Cycle 12 . If confirm , biopsy every 6 cycle long study . You also follow test procedures 1 time cycle start Cycle 10 : You physical exam , include pelvic exam . Blood ( 2 tablespoon ) draw routine test . If doctor think need , blood ( 1 teaspoon ) drawn check liver function . If disease appear gotten bad time Cycle 3 , 6 , 9 biopsy , stop take everolimus come study . The doctor talk surgical and/or non-surgical treatment option . If disease remain stable time Cycle 9 biopsy , come study doctor talk surgical and/or non-surgical treatment option . Biomarker Testing : Leftover tissue previous procedure test biomarkers . Biomarkers find blood/tissue may relate response levonorgestrel . Biomarker test also perform leftover tissue Month 3 EMB . End-of-Treatment Visit ( Arm 2 ) : After long receive study treatment ( ) : - You physical exam . - Blood ( 2 tablespoon ) draw routine test . This investigational study . The levonorgestrel IUD commercially available FDA approve form birth control . The use IUD treat endometrial cancer investigational . Everolimus FDA approve commercially available treat kidney , breast , pancreatic cancer . The combination everolimus levonorgestrel IUD study treat endometrial cancer investigational . Up 270 patient enrol study . Up 250 take part MD Anderson 20 take part Harris Health System .</detailed_description>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Levonorgestrel</mesh_term>
	<criteria>1 . All patient diagnosis complex atypical hyperplasia OR grade 1 endometrioid endometrial carcinoma endometrial biopsy D &amp; C within three month study enrollment 2 . Prior progesterone treatment either diagnosis ALLOWED . 3 . Ability comply endometrial biopsy every 3 month 4 . Age &gt; /= 18 year 5 . ECOG performance status &lt; /= 2 6 . Adequate bone marrow function show : absolute neutrophil count ( ANC ) &gt; /= 1.5 x 10^9/L ; Platelets &gt; /=100 x 10^9/L ; Hb &gt; 9 g/dL ; 7 . Adequate liver function show : ) Total serum bilirubin &lt; /= 2.0 mg/dL ; b ) Alanine aminotransferase ( ALT ) Aspartate aminotransferase ( AST ) &lt; /= 2.5x Upper Limit Normal ( ULN ) ; c ) International Normalized Ratio ( INR ) &lt; /= 2 8 . Adequate renal function : serum creatinine &lt; /=1.5x ULN 9 . Fasting serum cholesterol &lt; /= 300 mg/dL OR &lt; /= 7.75 mmol/L AND fast triglyceride &lt; /= 2.5x ULN . NOTE : In case one threshold exceed , patient include initiation appropriate lipid lowering medication ; 10 . Signed informed consent obtain prior screen procedure . 1 . Patients grade 23 endometrioid , uterine serous , clear cell , mucinous , squamous , transitional cell , sarcoma , carcinosarcoma histology 2 . Evidence extrauterine spread disease image surgical evaluation . 3 . Patients prior therapy everolimus mTOR inhibitor . 4 . Patients currently receive anticancer therapy ( include chemotherapy , radiation therapy , hormonal , antibodybased therapy ) . Prior treatment washout period 28 day 4 1/2 halflives ( 7 day ) , whichever short ; 5 . Known intolerance hypersensitivity everolimus rapamycin analog ( e.g . sirolimus , temsirolimus ) ; 6 . Known intolerance hypersensitivity progesterone excipients 7 . Known impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption oral everolimus ( e.g. , inability take oral medication requirement IV alimentation , prior surgical procedure affect absorption , malabsorption syndrome , active peptic ulcer disease ) exclude . Subjects ulcerative colitis , inflammatory bowel disease , partial complete small bowel obstruction also exclude , patient swallow capsule whole . 8 . Uncontrolled diabetes mellitus define HbA1c &gt; 8 % despite adequate therapy . Patients known history impair fast glucose diabetes mellitus ( DM ) may include , however blood glucose antidiabetic treatment must monitor closely throughout trial adjust necessary ; 9 . Patients severe and/or uncontrolled medical condition : a. unstable angina pectoris , symptomatic congestive heart failure , myocardial infarction &lt; /= 6 month prior start everolimus , serious uncontrolled cardiac arrhythmia , clinically significant cardiac disease b. Symptomatic congestive heart failure New York heart Association Class III IV c. active ( acute chronic ) uncontrolled severe infection , liver disease cirrhosis , decompensated liver disease , active chronic hepatitis ( i.e . quantifiable hepatitis B virusdeoxyribonucleic acid ( HBVDNA ) and/or positive Hepatitis B surface antigen ( HbsAg ) , quantifiable hepatitis C virusribonucleic acid ( HCVRNA ) , d. know severely impaired lung function ( spirometry Diffusing capacity Lung Carbon Monoxide [ DLCO ] 50 % less normal O2 saturation 88 % less rest room air ) , e. active , bleeding diathesis ; 10 . Chronic treatment corticosteroid immunosuppressive agent . Topical inhale corticosteroid allow 11 . Patients known history human immunodeficiency virus ( HIV ) seropositivity 12 . Patients receive live attenuate vaccine within 1 week start everolimus study . Patient also avoid close contact others receive live attenuate vaccine . Examples live attenuate vaccine include intranasal influenza , measles , mumps , rubella , oral polio , Bacillus CalmetteGu√©rin ( BCG ) , yellow fever , varicella TY21a typhoid vaccine 13 . Other malignancy within past 3 year except basal squamous cell carcinoma skin 14 . Active ( acute chronic ) uncontrolled severe infection , include acute pelvic inflammatory disease 15 . Congenital acquire uterine anomaly distorts uterine cavity 16 . Genital actinomycosis 17 . Patients history noncompliance medical regimen consider potentially unreliable able complete entire study 18 . Patients currently part participate clinical investigation investigational drug within 1 month prior dose . 19 . Women pregnant nursing ( lactate ) woman 20 . Women childbearing potential ( WOCBP ) , define woman physiologically capable become pregnant , must use one additional highly effective method contraception addition LIUD study 8 week . Acceptable effective contraception method include combo following : . Barrier method contraception : condom occlusive cap ( diaphragm cervical/vault cap ) spermicidal foam/gel/film/cream/ vaginal suppository ; b . Total abstinence ; c. Male/female sterilization . Women consider postmenopausal childbearing potential 12 month natural ( spontaneous ) amenorrhea appropriate clinical profile ( e.g . age appropriate , history vasomotor symptom ) surgical bilateral oophorectomy ( without hysterectomy ) tubal ligation &gt; six week prior randomization .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Endometrial Cancer</keyword>
	<keyword>Endometrial hyperplasia</keyword>
	<keyword>Intrauterine device</keyword>
	<keyword>IUD</keyword>
	<keyword>Levonorgestrel intrauterine device</keyword>
	<keyword>LIUD</keyword>
	<keyword>Mirena</keyword>
	<keyword>Everolimus</keyword>
	<keyword>Afinitor</keyword>
	<keyword>Zortress</keyword>
	<keyword>RAD001</keyword>
	<keyword>Questionnaires</keyword>
	<keyword>Survey</keyword>
	<keyword>Quality life</keyword>
	<keyword>QOL</keyword>
</DOC>